David Mack

List of Publications by Year in descending order

42 papers	5,954 citations	172457 29 h-index	265206 42 g-index
44 all docs	44 docs citations	44 times ranked	8697 citing authors

#	Article	IF	Citations
1	The Treatment-Naive Microbiome in New-Onset Crohnâ€™s Disease. Cell Host and Microbe, 2014, 15, 382-392.	11.0	2,582
2	Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience. Journal of Pediatric Gastroenterology and Nutrition, 2005, 41, 416-421.	1.8	271
3	Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children. Clinical Gastroenterology and Hepatology, 2008, 6, 1105-1111.	4.4	231
4	Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-Î± vs an Immunomodulator in Children With Crohn's Disease. Gastroenterology, 2014, 146, 383-391.	1.3	224
5	Metaproteomics reveals associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. Nature Communications, 2018, 9, 2873.	12.8	209
6	Mathematical weighting of the pediatric CrohnÊ¼s disease activity index (PCDAI) and comparison with its other short versions. Inflammatory Bowel Diseases, 2012, 18, 55-62.	1.9	203
7	Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host and Microbe, 2018, 24, 600-610.e4.	11.0	193
8	Long-term outcome of maintenance infliximab therapy in children with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 816-822.	1.9	165
9	Increased Intestinal Permeability Is Associated With Later Development of Crohnâ€™s Disease. Gastroenterology, 2020, 159, 2092-2100.e5.	1.3	156
10	Appraisal of the Pediatric Crohn's Disease Activity Index on Four Prospectively Collected Datasets: Recommended Cutoff Values and Clinimetric Properties. American Journal of Gastroenterology, 2010, 105, 2085-2092.	0.4	122
11	Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 2017, 152, 206-217.e2.	1.3	120
12	Corticosteroid Therapy in the Age of Infliximab: Acute and 1-Year Outcomes in Newly Diagnosed Children With Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1124-1129.	4.4	112
13	Functional Impacts of the Intestinal Microbiome in the Pathogenesis of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 139-153.	1.9	112
14	Variants in Nicotinamide Adenine Dinucleotide Phosphate Oxidase Complex Components Determine Susceptibility to Very Early Onset Inflammatory Bowel Disease. Gastroenterology, 2014, 147, 680-689.e2.	1.3	106
15	Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1748-1756.	4.4	90
16	Gut microbiota of the very-low-birth-weight infant. Pediatric Research, 2015, 77, 205-213.	2.3	85
17	Blenderized Enteral Nutrition Diet Study: Feasibility, Clinical, and Microbiome Outcomes of Providing Blenderized Feeds Through a Gastric Tube in a Medically Complex Pediatric Population. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1046-1060.	2.6	85
18	Deep Metaproteomics Approach for the Study of Human Microbiomes. Analytical Chemistry, 2017, 89, 9407-9415.	6.5	83

#	Article	IF	Citations
19	Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. Journal of Pediatrics, 2015, 167, 527-532.e3.	1.8	81
20	Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease?. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 254-260.	1.8	81
21	Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2014, 5, e46.	2.5	71
22	Intercenter variation in initial management of children with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2007, 13, 890-895.	1.9	67
23	Probiotics in Inflammatory Bowel Diseases and Associated Conditions. Nutrients, 2011, 3, 245-264.	4.1	62
24	Mucosa-Associated Ileal Microbiota in New-Onset Pediatric CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, 1533-1539.	1.9	43
25	To tell or not to tell: A qualitative interview study on disclosure decisions among children with inflammatory bowel disease. Social Science and Medicine, 2016, 162, 115-123.	3.8	42
26	Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping. PLoS ONE, 2015, 10, e0128074.	2.5	35
27	Anti-Microbial Antibody Response is Associated With Future Onset of Crohnâ€™s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology, 2021, 161, 1540-1551.	1.3	35
28	Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children. JAMA Pediatrics, 2017, 171, 984.	6.2	33
29	The mucosalâ€“luminal interface: an ideal sample to study the mucosa-associated microbiota and the intestinal microbial biogeography. Pediatric Research, 2019, 85, 895-903.	2.3	32
30	Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohnâ€™s disease. Nature Communications, 2020, 11, 4120.	12.8	32
31	Histologic analysis of eosinophils and mast cells of the gastrointestinal tract in healthy Canadian children. Human Pathology, 2016, 54, 55-63.	2.0	31
32	Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 829-838.	1.9	23
33	Independent of Birth Mode or Gestational Age, Very-Low-Birth-Weight Infants Fed Their Mothers' Milk Rapidly Develop Personalized Microbiotas Low in Bifidobacterium. Journal of Nutrition, 2018, 148, 326-335.	2.9	22
34	Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2019, 25, 1796-1804.	1.9	21
35	Children's perspectives on the benefits and burdens of research participation. AJOB Empirical Bioethics, 2018, 9, 19-28.	1.6	20
36	The effects of resistant starches on inflammatory bowel disease in preclinical and clinical settings: a systematic review and meta-analysis. BMC Gastroenterology, 2020, 20, 372.	2.0	17

#	Article	IF	Citations
37	Tolerability and SCFA production after resistant starch supplementation in humans: a systematic review of randomized controlled studies. American Journal of Clinical Nutrition, 2022, 115, 608-618.	4.7	14
38	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohnâ€™s disease subjects. BMC Medical Genetics, 2020, 21, 204.	2.1	11
39	Allied Health Professional Support in Pediatric Inflammatory Bowel Disease: A Survey from the Canadian Children Inflammatory Bowel Disease Networkâ€”A Joint Partnership of CIHR and the CH.I.L.D. Foundation. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-7.	1.9	10
40	CpG Methylation in TGFÎ²1 and IL-6 Genes as Surrogate Biomarkers for Diagnosis of IBD in Children. Inflammatory Bowel Diseases, 2020, 26, 1572-1578.	1.9	9
41	Fecal Markers of Inflammation and Disease Activity in Pediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 580-585.	1.8	8
42	Value of histopathology for predicting the post-operative complications of ileo-anal anastomosis (J-pouch) procedure in children with refractory ulcerative colitis. Pathology, 2016, 48, 330-335.	0.6	4